NOA-03 trial of high-dose methotrexate in primary central nervous system lymphoma: final report.
The NOA-03 trial explored high-dose methotrexate alone in 37 patients with primary central nervous system lymphoma. The overall median survival was 25 months. After 4 years, the rate of leukoencephalopathy in patients surviving more than 12 months was 58% with and 10% without whole-brain radiotherap...
Những tác giả chính: | Herrlinger, U, Küker, W, Uhl, M, Blaicher, H, Karnath, H, Kanz, L, Bamberg, M, Weller, M |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
2005
|
Những quyển sách tương tự
-
German Cancer Society Neuro-Oncology Working Group NOA-03 multicenter trial of single-agent high-dose methotrexate for primary central nervous system lymphoma.
Bằng: Herrlinger, U, et al.
Được phát hành: (2002) -
Primary central nervous system (CNS) lymphoma in immunocompetent patients.
Bằng: Plasswilm, L, et al.
Được phát hành: (2002) -
Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients.
Bằng: Küker, W, et al.
Được phát hành: (2005) -
Primary central nervous system lymphomas (PCNSL): MRI response criteria revised.
Bằng: Küker, W, et al.
Được phát hành: (2005) -
MRI features of primary central nervous system lymphomas at presentation.
Bằng: Bühring, U, et al.
Được phát hành: (2001)